Effects of the CYP 2D6 genotype and cigarette smoking on the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients

被引:21
作者
Gerstenberg, G
Aoshima, T
Fukasawa, T
Yoshida, K
Takahashi, H
Higuchi, H
Murata, Y
Shimoyama, R
Ohkubo, T
Shimizu, T
Otani, K [1 ]
机构
[1] Yamagata Univ, Sch Med, Dept Neuropsychiat, Yamagata 9900585, Japan
[2] Akita Univ, Sch Med, Dept Psychiat, Akita 010, Japan
[3] Hirosaki Univ Hosp, Dept Pharm, Hirosaki, Aomori, Japan
关键词
fluvoxamine; fluvoxamino acid; steady-state plasma concentration; CYP2D6; cigarette smoking;
D O I
10.1097/00007691-200308000-00008
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
The effects of the cytochrome P450 (CYP) 2D6 genotype and cigarette smoking on the steady-state plasma concentrations (C-SS) of fluvoxamine (FLV) and its demethylated metabolite fluvoxamino acid (FLA) were studied in 49 Japanese depressed patients receiving FLV 200 mg/d. The C-SS of FLV and FLA were measured by HPLC, and the wild-type allele (*1) and two mutated alleles causing absent (*5) or decreased (*10) CYP 2D6 activity were identified by PCR methods. The patients were divided into three genotype groups by the number of mutated alleles: 12 cases with no (*1/*1), 27 cases with one (*1/*5 and *1/*10), and 10 cases with two (*5/*10 and *10/*10) mutated alleles. The means +/- SD of the C-SS of FLV and FLA and the FLA/FLV ratio of all patients were 169.1 +/- 147.5 ng/mL, 83.9 +/- 52.7 ng/mL, and 0.71 +/- 0.50, respectively. The C-SS of FLV and FLA were not significantly different among the three genotype groups. However, the FLA/FLV ratio was significantly lower in the patients with one (P < 0.05) and two (P < 0.01) mutated alleles than in those with no mutated allele. There was no significant difference between nonsmokers (n = 34) and smokers (n = 15) in these values. In the stepwise multiple regression, the C-SS of FLA (P < 0.05) and FLA/FLV ratio (P < 0.001) showed significant negative correlations with the number of mutated alleles, and the FLA/FLV ratio was significantly (P < 0.05) lower in women than in men. The present study suggests that the CYP 2D6 genotype and cigarette smoking have no major impact on the C-SS of FLV and FLA, though CYP 2D6 is involved in the demethylation of FLV.
引用
收藏
页码:463 / 468
页数:6
相关论文
共 43 条
[1]   Polymorphic drug oxidation - Relevance to the treatment of psychiatric disorders [J].
Bertilsson, L ;
Dahl, ML .
CNS DRUGS, 1996, 5 (03) :200-223
[2]   THE INFLUENCE OF ENVIRONMENTAL AND GENETIC-FACTORS ON CYP2D6, CYP1A2 AND UDP-GLUCURONOSYLTRANSFERASES IN MAN USING SPARTEINE, CAFFEINE, AND PARACETAMOL AS PROBES [J].
BOCK, KW ;
SCHRENK, D ;
FORSTER, A ;
GRIESE, EU ;
MORIKE, K ;
BROCKMEIER, D ;
EICHELBAUM, M .
PHARMACOGENETICS, 1994, 4 (04) :209-218
[3]   Olanzapine - Pharmacokinetic and pharmacodynamic profile [J].
Callaghan, JT ;
Bergstrom, RF ;
Ptak, LR ;
Beasley, CM .
CLINICAL PHARMACOKINETICS, 1999, 37 (03) :177-193
[4]   Disposition of fluvoxamine in humans is determined by the polymorphic CYP2D6 and also by the CYP1A2 activity [J].
Carrillo, JA ;
Dahl, ML ;
Svensson, JO ;
Alm, C ;
Rodriguez, I ;
Bertilsson, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1996, 60 (02) :183-190
[5]   Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19) [J].
Christensen, M ;
Tybring, G ;
Mihara, K ;
Yasui-Furokori, N ;
Carrillo, JA ;
Ramos, SI ;
Andersson, K ;
Dahl, ML ;
Bertilsson, L .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (03) :141-152
[6]   REVIEW OF THE ANIMAL PHARMACOLOGY AND PHARMACOKINETICS OF FLUVOXAMINE [J].
CLAASSEN, V .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1983, 15 :S349-S355
[7]   Steady state plasma levels of nortriptyline and its 1.0-hydroxy metabolite: Relationship to the CYP2D6 genotype [J].
Dahl, ML ;
Bertilsson, L ;
Nordin, C .
PSYCHOPHARMACOLOGY, 1996, 123 (04) :315-319
[8]   NONLINEAR METABOLIC DISPOSITION OF THEOPHYLLINE [J].
DAHLQVIST, R ;
BILLING, B ;
MINERS, JO ;
BIRKETT, DJ .
THERAPEUTIC DRUG MONITORING, 1984, 6 (03) :290-297
[9]   SINGLE AND MULTIPLE ORAL DOSE FLUVOXAMINE KINETICS IN YOUNG AND ELDERLY SUBJECTS [J].
DEVRIES, MH ;
RAGHOEBAR, M ;
MATHLENER, IS ;
VANHARTEN, J .
THERAPEUTIC DRUG MONITORING, 1992, 14 (06) :493-498
[10]   EFFECTS OF SMOKING ON FLUPHENAZINE CLEARANCE IN PSYCHIATRIC-INPATIENTS [J].
ERESHEFSKY, L ;
JANN, MW ;
SAKLAD, SR ;
DAVIS, CM ;
RICHARDS, AL ;
BURCH, NR .
BIOLOGICAL PSYCHIATRY, 1985, 20 (03) :329-352